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Abstract
Recent studies demonstrated expression and activity of the intracellular cortisone-cortisol shuttle 11beta-hydroxysteroid
dehydrogenase type 1 (11beta-HSD1) in skeletal muscle and inhibition of 11beta-HSD1 in muscle cells improved insulin
sensitivity. Glucocorticoids induce muscle atrophy via increased expression of the E3 ubiquitin ligases Atrogin-1 (Muscle
Atrophy F-box (MAFbx)) and MuRF-1 (Muscle RING-Finger-1). We hypothesized that 11beta-HSD1 controls glucocorticoid-
induced expression of atrophy E3 ubiquitin ligases in skeletal muscle. Primary human myoblasts were generated from
healthy volunteers. 11beta-HSD1-dependent protein degradation was analyzed by [
3H]-tyrosine release assay. RT-PCR was
used to determine mRNA expression of E3 ubiquitin ligases and 11beta-HSD1 activity was measured by conversion of
radioactively labeled [
3H]-cortisone to [
3H]-cortisol separated by thin-layer chromatography. We here demonstrate that
11beta-HSD1 is expressed and biologically active in interconverting cortisone to active cortisol in murine skeletal muscle
cells (C2C12) as well as in primary human myotubes. 11beta-HSD1 expression increased during differentiation from
myoblasts to mature myotubes (p,0.01), suggesting a role of 11beta-HSD1 in skeletal muscle growth and differentiation.
Treatment with cortisone increased protein degradation by about 20% (p,0.001), which was paralleled by an elevation of
Atrogin-1 and MuRF-1 mRNA expression (p,0.01, respectively). Notably, pre-treatment with the 11beta-HSD1 inhibitor
carbenoxolone (Cbx) completely abolished the effect of cortisone on protein degradation as well as on Atrogin-1 and MuRF-
1 expression. In summary, our data suggest that 11beta-HSD1 controls glucocorticoid-induced protein degradation in
human and murine skeletal muscle via regulation of the E3 ubiquitin ligases Atrogin-1 and MuRF-1.
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Introduction
Glucocorticoid excess is associated with central obesity, insulin
resistance, arterial hypertension and skeletal muscle atrophy.
Intracellular glucocorticoid signaling is pre-receptor-controlled by
11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)
which activates cortisol from the hormonally inactive cortisone.
Increased 11beta-HSD1 activity has been associated with
symptoms of the metabolic syndrome. Although obese individuals
have normal cortisol plasma levels, intracellular glucocorticoid
action in liver and adipose tissue were shown to be increased in
some publications due to high 11beta-HSD1 expression levels and
activity [1], [2], [3]. Transgenic mice over-expressing 11beta-
HSD1 specifically in adipose tissue gained weight and developed
insulin resistance and dyslipidemia [4]. In contrast, 11beta-HSD1
knockout mice were resistant to obesity and hyperglycemia under
a high-fat diet [5].
In adipose tissue and liver, the function of 11beta-HSD1 is well
studied but data about its role in skeletal muscle are sparse
although it is well known that glucocorticoids induce muscle
atrophy by inhibition of protein synthesis and induction of protein
degradation [6], [7]. Very recently, expression and activity of
11beta-HSD1 was shown to be increased in skeletal muscle of
diabetic individuals [8] and pharmacological inhibition of 11beta-
HSD1 reversed cortisone-disturbed insulin signaling in skeletal
muscle cells [9]. 11beta-HSD1 was also suggested to be involved in
the differentiation of skeletal myoblasts to mature myotubes due to
an increasing 11beta-HSD1 expression during the differentiation
process, shown in the skeletal muscle C2C12 cell line [10], [11].
Despite those convincing data that 11beta-HSD1 is functionally
active in skeletal muscle, the underlying role of this enzyme for
muscle atrophy associated pathways is still unclear. Glucocorti-
coids are well established to induce skeletal muscle proteolysis
primarily by activating the ubiquitin-proteasome-system (UPS)
and increasing the expression of the two E3 ubiquitin ligases
Atrogin-1 and MuRF-1 [12], [13], [14], [15].
We therefore analyzed in the skeletal muscle cell line C2C12
and in primary human myotubes whether 11beta-HSD1 controls
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The C2C12 murine myoblast cell line and primary human
myoblasts were grown under standard conditions. For C2C12,
growth medium consisted of Dulbecco’s modified Eagle’s medium
(DMEM) including 4.5 g/L glucose and stable glutamine,
supplemented with 10% fetal calf serum (FCS). Primary human
myoblast cultures were isolated by protease digestion from fresh
muscle biopsies (collagenase II, dispase1, trypsin/EDTA) and
expanded in skeletal muscle growth medium including supplement
mix (PromoCell, Heidelberg, Germany), 10% FCS, glutamine
(3 mM) and gentamycin (40 mg/ml). All cultures were enriched in
myoblasts by immuno-magnetic cell sorting using anti-CD56/
NCAM antibody coated magnetic beads (Miltenyi Biotech,
Bergisch Gladbach, Germany). Purity of the myoblast preparation
was checked by staining with an anti-desmin antibody revealing
more than 95% desmin-positive cells. All experiments were
performed between passage P5 and P15 after isolation to avoid
premature replicative senescence. Differentiation of myoblasts into
myotubes was initiated at approximately 90% confluence by
switching to differentiation medium containing 2% horse serum
(D0, day 0 of differentiation). For stimulation experiments,
myotubes were serum-starved and on day six of differentiation
(D6) 30–60 min pre-treated with 10 mM carbenoxolone (Sigma-
Aldrich Chemie GmbH, Munich, Germany), followed by
incubation with 1 mM cortisone (Sigma-Aldrich Chemie GmbH,
Munich, Germany) and 1 mM dexamethasone (Sigma-Aldrich
Chemie GmbH, Munich, Germany) for sixteen hours.
Real-time PCR
Total RNA was isolated using a commercial RNA isolation kit
(Roche Diagnostics GmbH, Mannheim, Germany). cDNA was
also synthesized according to manufacturer’s protocol (Applied
Biosystems, Darmstadt, Germany). Real-time PCR (RT-PCR) was
analyzed using Power Sybr Green (Applied Biosystems, Darm-
stadt, Germany) on a 7300 Real-Time PCR System (Applied
Biosystems, Darmstadt, Germany) or by TaqMan Technology
(Applied Biosystems, Darmstadt, Germany). All experiments were
performed at least in triplicate. The PCR primer sequences will be
provided upon request.
11beta-HSD1 activity assay
11beta-HSD1 activity was measured as described previously
[16]. Briefly, we determined the conversion of radioactively
labeled [
3H]-cortisone to [
3H]-cortisol. Cells were incubated with
0.1 mCi 1,2-[
3H]-Cortisone (American Radiolabeled Chemicals,
Inc., St. Louis, USA) at 37uC and 5% CO2 for at least four hours
in serum-free DMEM. Then, medium supernatant was collected
and cells were lysed with 50 mM NaOH. An aliquot of cell lysate
was used to determine DNA concentration in a photometer at
260 nm. Supernatant and cell lysate were mixed with 2–3 volumes
of ethyl-acetate (Merck, Darmstadt, Germany) by shaking and
lower hydrophil and upper lipophil phases were separated by
centrifugation. The upper steroid containing phase was fully
evaporated under air, resolved in dichlormethane (Carl Roth
GmbH + Co. KG, Karlsruhe, Germany) and cortisone (E) and
cortisol (F) separated by thin-layer chromatography using
dichlormethane:methanol (75:5) as solvent. [
3H]-labeled cortisone
and cortisol were quantified in a beta-counter.
Protein degradation
Proteolysis was measured by determining the rate of release of
trichloroacetic acid (TCA)-soluble proteins radioactively labeled
with [
3H]-tyrosine into the media. On day five of differentiation,
cells were pre-labeled with 0.5 mCi L-[3,5-
3H]-tyrosine/ml (Bio-
trendGmbH,Ko ¨ln,Germany)at37uCand5%CO2fortwodaysin
differentiation medium. The cells were washed once with hank’s
buffered salt solution (HBSS) and transferred to non-radioactive
serum-free DMEM containing 2 mM tyrosine for two hours to
exclude proteolysis of short-lived proteins. Then the cells were
washed twice with HBSS and again transferred to non-radioactive
serum-free DMEM containing 2 mM tyrosine. Release of [
3H]-
tyrosine was measured after pre-treatment with 10 mM carbenox-
olone for 30–60 min followed by stimulation with 1 mM cortisone
and 1 mM dexamethasone. After 16 hours incubation, culture
medium was transferred to a microcentrifuge tube containing
100 ml bovine serum albumin (BSA) (10 mg/ml). For precipitation,
an equal volume of TCA (20% wt/vol) was added to a final
concentration of 10% (wt/vol) and incubated at 4uC for at least one
hour until overnight. Samples were then centrifuged at 14000 g for
5 min. The supernatant contained the TCA-soluble proteins
(fraction A). The TCA-insoluble proteins in the precipitate were
solubilized in 0.5 M NaOH und 0.1% Triton X100 (fraction B).
The cell monolayer was washed twice with phosphate buffered
saline (PBS) and also solubilized in 0.5 M NaOH and 0.1% Triton
X100 (fraction C). [
3H]-labeled tyrosine within the three fractions
was quantified using a beta-counter. Percentage protein degrada-
tion was calculated as 1006[fraction A/(fraction A+B+C)].
Statistics
Results are presented as means 6 SEM. Mann-Whitney-U test
was used to analyze differences between groups. Significance was
considered for p,0.05. All experiments were performed at least in
triplicate.
Results
11beta-HSD1 expression increases during myoblast
differentiation
To test whether 11beta-HSD1 expression depends on the
differentiation process of skeletal muscle cells from myoblasts to
adult myotubes, we measured mRNA expression of 11beta-HSD1
and the differentiation markers Myosin Heavy chain-1 and Myf5
at different time points (day 0 (D0), day 2 (D2), day 4 (D4) and day
(D6)). Expression of Myosin Heavy chain-1 (marker of terminal
differentiation) strongly increased from D0 to D6 (Fig. 1B and 1E)
confirming differentiation into adult myotubes. Additionally, Myf5
mRNA expression (marker of myoblast fusion) reached a plateau
on D2 (Fig. 1C). 11beta-HSD1 mRNA expression was low in
myoblasts (D0) and increased at D6 by factor 351.2648.6
(p,0.01) in C2C12 cells (Fig. 1A) and 4.761.9 (p,0.01) in
primary human myotubes (Fig. 1D), whereas 11beta-HSD1 was
already higher expressed in undifferentiated primary human
myoblasts than in C2C12 myoblasts. In summary, we demonstrate
that 11beta-HSD1 mRNA expression is induced within the
differentiation process of the murine C2C12 cell line, but also in
primary human myoblasts.
11beta-HSD1 controls glucocorticoid-induced proteolysis
and expression of the E3 ubiquitin ligases Atrogin-1 and
MuRF-1
To analyze the role of 11beta-HSD1 on skeletal muscle
proteolysis, we induced 11beta-HSD1 activity by stimulation with
HSD1 and Skeletal Muscle Proteolysis
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carbenoxolone (Fig. 2). We observed an increased proteolysis in
cortisone-treated C2C12 myotubes (E 120.361.7% vs. control,
p,0.001) (Fig. 3). This was paralleled by a cortisone-dependent
increase of the E3 ubiquitin ligases Atrogin-1 (2.8460.4 vs.
control, p,0.01) (Fig. 4A) and MuRF-1 (1.9160.4 vs. control,
p,0.01) (Fig. 4B). We next analyzed the role of 11beta-HSD1 in
the regulation of protein degradation and those E3 ubiquitin
ligases. Indeed, the cortisone-induced increase of protein degra-
dation was completely abolished by pre-inhibition of 11beta-
HSD1 with carbenoxolone (E+Cbx 96.561.3% vs. control,
p,0.001) (Fig. 3). Comparably, inhibition of 11beta-HSD1
completely abolished the effect of cortisone on Atrogin-1
(E+Cbx 1.0560.1 vs. control, p,0.01) and MuRF-1 (E+Cbx
Figure 1. Regulation of 11beta-HSD1 and differentiation markers during differentiation of C2C12 cells and primary human
myoblasts. Data were normalized to mRNA expression of 16s-RiboProtein. Mean 6 SEM of at least three experiments are shown. Relative 11beta-
HSD1 mRNA expression in C2C12 (A). Relative Myosin Heavy Chain-1 mRNA expression in C2C12 cells (B). Relative Myf5 mRNA expression in C2C12
cells (C). Relative 11beta-HSD1 mRNA expression in primary human myoblasts (D). Relative Myosin Heavy Chain-1 mRNA expression in primary
human myoblasts (E). * p,0.05, ** p,0.01, *** p,0.0001.
doi:10.1371/journal.pone.0016674.g001
HSD1 and Skeletal Muscle Proteolysis
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e166740.9460.1 vs. control, p,0.01) (Fig. 4A and 4B). These results were
basically confirmed in primary human myotubes (MuRF-1:
E+Cbx 1.260.3 vs. E 1.960.1, p,0.05), although slightly failing
significance for Atrogin-1 (1.160.2 vs. E 1.460.1, p=0.3)
(Fig.4C and 4D).
Discussion
Here we demonstrate that 11beta-HSD1 controls glucocorti-
coid-induced protein degradation and transcription of the E3
ubiquitin ligases Atrogin-1 and MuRF-1 in the skeletal muscle cell
line C2C12 and in primary human myotubes. In addition, we
show that 11beta-HSD1 mRNA expression increases during
differentiation of primary human myoblasts to mature myotubes
indicating a role of 11betaHSD1 in differentiation of myocytes.
Atrogin-1 and MuRF-1 are upregulated in various models of
muscle atrophy and are considered to serve as reliable markers of
muscular atrophy [17], [18], [19]. An increased expression of
Atogin-1 and MuRF-1 strongly indicates an enhanced proteolysis
via the UPS, and several studies demonstrated that glucocorticoids
induce muscle proteolysis via Atrogin-1 and MuRF-1 [12], [13],
[14], [17]. This is supported by our results showing glucocorticoid-
induced increases of proteolysis and atrophy signaling. In addition
to existing data our results demonstrate that glucocorticoid-
dependent effects are partially pre-receptor controlled by 11beta-
HSD1. A limitation of our study is the use of carbenoxolone as a
pharmacological 11beta-HSD1 inhibitor. Although carbenoxo-
lone is an established inhibitor of 11beta-HSD1 and we achieved a
near-complete inhibition of 11beta-HSD1 activity in our exper-
iments, we cannot entirely exclude unspecific effects. Clearly, the
confirmation of our results in animal experiments e.g. using mice
with myocyte-specific 11beta-HSD1 knock-out would be highly
desirable. Vice versa, a specific strength of our study is the
confirmation of those results in human myotubes, pointing
towards a physiological relevance of the findings in humans.
Previous studies suggested 11beta-HSD1 mRNA expression in
skeletal muscle [8], [20], [21] and recent data supported that
11beta-HSD1 controls metabolic phenotypes in skeletal muscle
such as insulin sensitivity. Morgan et al. (2009) showed that
pharmacological inhibition of 11beta-HSD1 in mice reversed
cortisone-disturbed insulin signaling pathway in skeletal muscle
cells by blocking amongst others the decrease of Akt/PKB
phosphorylation [9]. The PI3K/Akt pathway is also involved in
the proteolytic signaling cascade in skeletal muscle. Thus, the
activation of the PI3K/Akt pathway is diminished in myotubes
undergoing atrophy [22]. Accordingly, glucocorticoids decrease
Akt/PKB phosphorylation followed by an activation of the
Forkhead box O (Foxo) class transcription factors causing
activation of the Atrogin-1 promoter and a decrease in muscle
fiber size [23]. Our data strongly support that atrophy signaling in
skeletal muscle also depends on pre-receptor controlled mecha-
nisms. Theoretically, the observed effects on atrophy signaling
may depend on the associated metabolic consequences or vice
versa, although this is unlikely given the setting of our studies
which were performed without insulin stimulation. Nevertheless,
this question was not directly addressed and we cannot exclude
that a modification of basal insulin sensitivity may link glucocor-
ticoids, 11beta-HSD1 and atrophy signaling.
In conclusion, our data suggest that 11beta-HSD1 controls
glucocorticoid-induced protein degradation in skeletal muscle by
regulating the expression of the muscle ubiquitin E3 ligases
Atrogin-1 and MuRF-1.
Figure 2. Effects of cortisone, dexamethasone (dexa) and
inhibition of 11beta-HSD1 by carbenoxolone (Cbx) on 11be-
ta-HSD1 activity in C2C12. Mean 6 SEM of at least three
experiments are shown. * p,0.05, ** p,0.01, *** p,0.0001.
doi:10.1371/journal.pone.0016674.g002
Figure 3. Effects of cortisone, dexamethasone (dexa) and
inhibition of 11beta-HSD1 by carbenoxolone (Cbx) on protein
degradation in C2C12 myotubes. Protein degradation was
measured by determining the rate of release of TCA-soluble proteins
radioactively labeled with [
3H]-tyrosine into the media. Mean 6 SEM
of at least three experiments are shown. * p,0.05, ** p,0.01,
*** p,0.0001.
doi:10.1371/journal.pone.0016674.g003
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